Výsledky vyhledávání - "María Jesús Ortiz-Ruiz"

Data from Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor

Autor: Atanasio Pandiella, Azucena Esparís-Ogando, Francis J. Burrows, Jesús San Miguel, Enrique M. Ocio, Sara Zaknoen, Tracy Parrott, María Jesús Ortiz-Ruiz, Stela Álvarez-Fernández

Purpose: To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug.Experimental Design: Utilizing different multiple myeloma cell lines we determined the effect of TG02 over viability by MTT assays. The apoptotic effect over multiple

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::992eac3a070d9fa9c2a0355ce6083f3e
https://doi.org/10.1158/1078-0432.c.6520782

Zobrazit plný text záznamu

Akademický článek

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.

Autor: Juan Carlos Montero, Alberto Ocaña, Mar Abad, María Jesús Ortiz-Ruiz, Atanasio Pandiella, Azucena Esparís-Ogando

Publikováno v: PLoS ONE, Vol 4, Iss 5, p e5565 (2009)

BACKGROUND: Breast cancer is the most common neoplasia in women. Even though advances in its treatment have improved disease outcome, some patients relapse. Therefore, attempts to better define the molecular determinants that drive breast cancer cell

Externí odkaz: https://doaj.org/article/54878656132349f8b6aa66b08c130f59

Zobrazit plný text záznamu

MEK5 promotes lung adenocarcinoma

Autor: María Florencia Re-Louhau, Adrián Sánchez-Fdez, Dolores Ludeña, Óscar Blanco-Múñez, Azucena Esparís-Ogando, Isabel Ramos, Manuel Sánchez-Martín, María Jesús Ortiz-Ruiz, M. Abad, Atanasio Pandiella

Publikováno v: The European Respiratory Journal

Lung cancer represents the leading cause of cancer death worldwide [1]. Because of that, intense efforts are being devoted to the development of novel therapeutic strategies to fight the disease [2]. In this respect, identification of new oncogenic d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b45cbcbd1087ee4b6df2aa20214e5515
http://europepmc.org/articles/PMC6393765

Zobrazit plný text záznamu

Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor

Autor: Enrique M. Ocio, Francis Burrows, María Jesús Ortiz-Ruiz, Sara Zaknoen, Stela Álvarez-Fernández, Tracy Parrott, Atanasio Pandiella, Jesús F. San Miguel, Azucena Esparís-Ogando

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname

[Purpose]: To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug. [Experimental Design]: Utilizing different multiple myeloma cell lines we determined the effect of TG02 over viability by MTT assays. The apoptotic effect over mult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b05d0e29457f5315e02b860e90d781
https://doi.org/10.1158/1078-0432.ccr-12-2118

Zobrazit plný text záznamu

Therapeutic potential of ERK5 targeting in triple negative breast cancer

Autor: Alberto Ocaña, María Jesús Ortiz-Ruiz, Sara Zaknoen, Azucena Esparís-Ogando, Francis Burrows, Atanasio Pandiella, Stela Álvarez-Fernández, Tracy Parrott

Publikováno v: ResearcherID
Oncotarget
Digital.CSIC. Repositorio Institucional del CSIC
instname
Scopus-Elsevier
Europe PubMed Central

Licensed under a Creative Commons Attribution 3.0 License.
Triple negative breast cancers (TNBCs) account for 15% of all breast cancers, and represent one of the most aggressive forms of the disease, exhibiting short relapse-free survival. In co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b09fe705a382c6e2c6c721c178bc0cc
http://hdl.handle.net/10261/134056

Zobrazit plný text záznamu

Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target

Autor: María Jesús Ortiz-Ruiz, Alberto Ocaña, María del Mar Abad, Azucena Esparís-Ogando, Atanasio Pandiella, Juan Carlos Montero

Publikováno v: PLoS ONE
PLoS ONE, Vol 4, Iss 5, p e5565 (2009)

Background Breast cancer is the most common neoplasia in women. Even though advances in its treatment have improved disease outcome, some patients relapse. Therefore, attempts to better define the molecular determinants that drive breast cancer cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4bb28694ed5c7ffc851d027feac03d
http://europepmc.org/articles/PMC2678256

Zobrazit plný text záznamu

Abstract A153: Effect of the multikinase inhibitor TG02 in HER2-positive breast cancer

Autor: Azucena Esparís-Ogando, Atanasio Pandiella, Francis Burrows, María Jesús Ortiz-Ruiz

Publikováno v: Molecular Cancer Therapeutics. 10:A153-A153

Breast cancer represents a heterogeneous disease in which several distinct genetic and histopathological types have been defined. Depending on the latter, treatment is established based on the presence of estrogen or progesterone receptors, the trans

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e53e4bc49bf2d820177a62698963db5
https://doi.org/10.1158/1535-7163.targ-11-a153

Zobrazit plný text záznamu

Abstract B268: Tyrosine kinase profiling in head and neck cancer tumors in combination with clinical prognosis factors guides therapeutic combination strategies

Autor: Rafael Lopez‐Castro, Juan Jesús Cruz, María Jesús Ortiz-Ruiz, Atanasio Pandiella, Ruth Rodriguez-Barrueco, Alberto Ocaña

Publikováno v: Molecular Cancer Therapeutics. 8:B268-B268

Background: Tyrosine kinases (TK) are a particular subgroup of proteins implicated in the genesis/progression of Squamous cell carcinoma of the head and neck (SCCHN). Therapeutic inhibition of several of them has shown to be clinically useful, as is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a69700433eb9cc785add6da34b2d2e4
https://doi.org/10.1158/1535-7163.targ-09-b268

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání